Abstract
The discovery of new compounds with antitumoral activity has become one of the most important goals in medicinal chemistry. One interesting group of chemotherapeutic agents used in cancer therapy comprises molecules that interact with DNA. Research in this area has revealed a range of DNA recognizing molecules that act as antitumoral agents, including groove binders, alkylating and intercalator compounds. DNA intercalators (molecules that intercalate between DNA base pairs) have attracted particular attention due to their antitumoral activity. For example, a number of acridine and anthracycline derivatives are excellent DNA intercalators that are now on the market as chemotherapeutic agents. Commercially available acridine and anthracycline derivatives have been widely studied from a variety of viewpoints, such as physicochemical properties, structural requirements, synthesis and biological activity. However, the clinical application of these and other compounds of the same class has encountered problems such as multidrug resistance (MRD), and secondary and / or collateral effects. These shortcomings have motivated the search for new compounds to be used either in place of, or in conjunction with, the existing compounds. Unfortunately, the results of this search have not met expectations. The vast majority of candidate intercalator compounds tested for use as anticancer agents have shown little or no biological activity. Research in this area has not been without benefits, however, for it has produced much information on the synthesis and antitumoral properties of hundreds of compounds, which have been tested on diverse tumoral cell lines. This review considers the structural and biological considerations relevant to the use of DNA intercalators and bis-intercalators as antitumoral agents, with an emphasis on the relationship between structure and activity, produced in last decade.
Keywords: dna- intercalators, cytotoxic compounds, dna-binding
Current Medicinal Chemistry
Title: The Search of DNA-Intercalators as Antitumoral Drugs: What it Worked and What did not Work
Volume: 12 Issue: 2
Author(s): R. Martinez and L. Chacon-Garcia
Affiliation:
Keywords: dna- intercalators, cytotoxic compounds, dna-binding
Abstract: The discovery of new compounds with antitumoral activity has become one of the most important goals in medicinal chemistry. One interesting group of chemotherapeutic agents used in cancer therapy comprises molecules that interact with DNA. Research in this area has revealed a range of DNA recognizing molecules that act as antitumoral agents, including groove binders, alkylating and intercalator compounds. DNA intercalators (molecules that intercalate between DNA base pairs) have attracted particular attention due to their antitumoral activity. For example, a number of acridine and anthracycline derivatives are excellent DNA intercalators that are now on the market as chemotherapeutic agents. Commercially available acridine and anthracycline derivatives have been widely studied from a variety of viewpoints, such as physicochemical properties, structural requirements, synthesis and biological activity. However, the clinical application of these and other compounds of the same class has encountered problems such as multidrug resistance (MRD), and secondary and / or collateral effects. These shortcomings have motivated the search for new compounds to be used either in place of, or in conjunction with, the existing compounds. Unfortunately, the results of this search have not met expectations. The vast majority of candidate intercalator compounds tested for use as anticancer agents have shown little or no biological activity. Research in this area has not been without benefits, however, for it has produced much information on the synthesis and antitumoral properties of hundreds of compounds, which have been tested on diverse tumoral cell lines. This review considers the structural and biological considerations relevant to the use of DNA intercalators and bis-intercalators as antitumoral agents, with an emphasis on the relationship between structure and activity, produced in last decade.
Export Options
About this article
Cite this article as:
Martinez R. and Chacon-Garcia L., The Search of DNA-Intercalators as Antitumoral Drugs: What it Worked and What did not Work, Current Medicinal Chemistry 2005; 12 (2) . https://dx.doi.org/10.2174/0929867053363414
DOI https://dx.doi.org/10.2174/0929867053363414 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
On Performance of Feature Normalization in Classification with Distance-Based Case-Based Reasoning
Recent Patents on Computer Science Cucurbitacins as Anticancer Agents: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Predicting Type-I (Rate-Shift) Functional Divergence of Protein Sequences and Applications in Functional Genomics
Current Genomics Peptide-Mediated Delivery of Therapeutic and Imaging Agents Into Mammalian Cells
Current Pharmaceutical Design Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry Nature Inspired Green Fabrication Technology for Silver Nanoparticles
Current Nanomedicine VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Promising Chemoprevention of Colonic Aberrant Crypt Foci by <i>Portunus segnis</i> Muscle and Shell Extracts in Azoxymethane-Induced Colorectal Cancer in Rats
Anti-Cancer Agents in Medicinal Chemistry The Chemistry of Bisphosphonates: From Antiscaling Agents to Clinical Therapeutics
Anti-Cancer Agents in Medicinal Chemistry The Cross-talk between Tristetraprolin and Cytokines in Cancer
Anti-Cancer Agents in Medicinal Chemistry Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Current Cancer Drug Targets Recent Advances on Patents in Poly(Ethylene Glycol)-Based Drug Delivery
Recent Patents on Drug Delivery & Formulation Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Role of Membrane Transporters and Metabolizing Enzymes in Ocular Drug Delivery
Current Drug Metabolism The Key microRNAs Regulated the Development of Non-small Cell Lung Cancer by Targeting TGF-β-induced epithelial–mesenchymal Transition
Combinatorial Chemistry & High Throughput Screening Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Clinical Cancer Drugs Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Current Pharmaceutical Design Graphene-based Biosensors for Biomolecules Detection
Current Nanoscience